Evidence map›Paper›PMID 41770916›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

HES1 oscillations are required for cell cycle reentry in oestrogen receptor-positive breast cancer cells.

Oliver Cottrell, Andrew Rowntree, Kunal Chopra, Eleanor Mackellar, Benjamin Noble, Hannah L Dixon, Ciara Healy, Robert B Clarke, Nancy Papalopulu

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. HES1 oscillations are required for cell cycle reentry in oestrogen receptor-positive breast cancer cells.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Oliver CottrellDivision of Developmental Biology and Medicine, School of Medical Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom.ORCID 0000-0002-8881-8645
Andrew RowntreeDivision of Developmental Biology and Medicine, School of Medical Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom.ORCID 0000-0003-3220-0720
Kunal ChopraDivision of Developmental Biology and Medicine, School of Medical Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom.
Eleanor MackellarDivision of Developmental Biology and Medicine, School of Medical Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom.
Benjamin NobleDivision of Developmental Biology and Medicine, School of Medical Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom.
Hannah L DixonSafety Science Group, ApconiX, Alderley Edge SK10 4TG, United Kingdom.
Ciara HealyDivision of Developmental Biology and Medicine, School of Medical Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom.
Robert B ClarkeManchester Breast Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Oglesby Cancer Research Building, Manchester M20 4GJ, United Kingdom.
Nancy PapalopuluDivision of Developmental Biology and Medicine, School of Medical Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom.ORCID 0000-0001-6992-6870

Funding

Cancer Research UK (CRUK) DRCMDP-Nov22/100009UKRI | Medical Research Council (MRC) P119489Wellcome Trust (WT) 224394/Z/21/Z
6 · The paper itself

Abstract

Long-term recurrence in breast cancer is driven by reactivation of dormant disseminated tumor cells (DTCs) and remains a major clinical challenge, particularly in estrogen receptor-positive (ER

Indexed as

Breast NeoplasmsCell CycleReceptors, EstrogenTranscription Factor HES-1Cell Cycle CheckpointsCell Line, TumorCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6FemaleGene Expression Regulation, NeoplasticHumansPiperazinesPyridinesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6HES1 protein, humanpalbociclibPiperazinesPyridinesReceptors, EstrogenTranscription Factor HES-1breast cancercell cycledormancy and reactivationHES1oscillations

Identifiers

PMID41770916
PMCPMC12974427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.